The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q1 2016 call → NOWe need to determine if management conveys that the reported results for the period (Q1 2016) do not represent the business as it is actually running today. The call discusses CUDC-907 and CA170. Management notes that CUDC-907 Phase 2 trial was initiated in January 2016, and they have completed enrollment in the monotherapy arm of Phase 1, with updated data. They also mention CA170 is expected to enter the clinic later this quarter. They also mention new studies for Erivedge. The financial results show a net loss of $9.4 million vs $31.8 million prior year, with the prior year including a one-time charge. Revenues were $1.7 million. R&D expenses increased due to clinical activities. The overall tone is about progress and ongoing trials. Is there a sense that the reported period is stale relative to the operating present? Management highlights that the Phase 2 trial was initiated in January 2016, and they have completed enrollment in the Phase 1 monotherapy arm, with updated data. They also expect CA170 to enter the clinic later this quarter. These are recent developments that are not reflected in the reported period. However, the question asks if management conveys that the reported results do not represent the business they are actually running today. They are describing ongoing progress, but is it a substantial gap? The reported period is Q1 2016, and the call is in May 2016. They mention that they have completed enrollment in the Phase 1 monotherapy arm, which is a recent event. They also mention that CA170 is expected to enter the clinic later this quarter, which is after the period. They also mention new studies for Erivedge. But is management saying that the business has moved to a different level? They are not explicitly saying that the reported numbers are stale. They are providing updates on ongoing trials. The question asks if management repeatedly or substantially indicates that the just-reported numbers describe a company that has already been left behind. The call is a standard earnings call with updates. There is no strong language about the period being unrepresentative. The financial results are straightforward. The R&D increase is due to ongoing clinical activities. The company is progressing, but it's not a case where the reported period is a different business. The answer is likely NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.